HUE033776T2 - FVIII helyspecifikus módosítása - Google Patents

FVIII helyspecifikus módosítása Download PDF

Info

Publication number
HUE033776T2
HUE033776T2 HUE05849392A HUE05849392A HUE033776T2 HU E033776 T2 HUE033776 T2 HU E033776T2 HU E05849392 A HUE05849392 A HU E05849392A HU E05849392 A HUE05849392 A HU E05849392A HU E033776 T2 HUE033776 T2 HU E033776T2
Authority
HU
Hungary
Prior art keywords
leu
ser
fviii
thr
lys
Prior art date
Application number
HUE05849392A
Other languages
English (en)
Inventor
Clark Q Pan
John E Murphy
Baisong Mei
Jonathan S Strauss
Hendri Tjandra
Jianmin Chen
Thomas Barnett
Liang Tang
Deqian Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033776(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HUE033776T2 publication Critical patent/HUE033776T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Claims (5)

  1. SaafeaáalM iféóypóhink l.: VHI'^i :S|skíöí' p<5feí};^k!sfes~sktj¥|tS5Ö. koi\j«g$|.utík. amely működőképes Vpl-aS: .tirtutamz. axndy oly módon orcialédoíí, Hagy legalább egy, ossjstemtöll klHötroozó anpríossv· clsziein atmnossv> •val helyettesített, ezáltal matins císxtem siamósav vsa; jeléig #«>1 a -működőképes kAlEgs faktor pollppöá.a. «Iss ¢^¾ :pafe^sr«Ä fc&amp;vatóisse« a^fe^kosiipatfhilis polimerbe/ kapchOb. ahol &amp; fciokornpstihlHs polipéba VÏH-as faktor kővetkező aminasavpozíeiöi egyikéné; kapcsolódik kovalensen a poHpeptídhez: 8K 129} 377, 3?h, 468. 4S?: 491, m, 336, ViO. 1648, Π95, 1796, 1803, ISIM, HÚS, IS Hi. M, 1313, ISIS, lÄ jóii, 209 1,21 18 és 2284,
  2. 3, Az k igégyppat sprinthfecapagsAatt, ahol a 3 A/ 1 igénypont szerinti konjugátunt. ahol a működőképes V likas faktor pollpeptid B-doínérideleták Vlík-aS faktor, 4, A 3v igénypont szerinti konjsg&amp;txm. ahol B-dontén-deklálf Völ^astMtorltxJS -a.:|ikikomptll?tliS· pík tnar kovaiföKsst; kap!!i5§^iöd^sM^^0*l::^lÄ.avi)0?4a|ii8^:Äik0ß: 129,491, 4$Ö4 ssigy IMS; a 491- atnmo-saxópoxféiébas biölstnpatibÄ ftolimet k.§j$Ä0dik és egy stlsodlk biokótapalifellis firmer kapcsolódik m,·. 1808. amiae^-wg:e$cióban; vagy a 491. aminosav«pozícióba» biokoropatibiiis politriér képsölödtk:4s egy második biökötnpatlhsHs polimer kapcsolódik az 1804. aonnosav-pozielóban.
  3. 5, Az 1. igénypont szerinti konjugámm. ahol a működőképes VHEös faktor pollpeptid arnlnosav-szekvenciája a 8BQ ÍD NO: 4 vagy SEQ ÍD NO: 3 szerinti szekvencia. 4 Az I - igéöjfotk sgcríati kóí|üganifn; akof a móködókepey NZIIÍaís íaklöt |ölpéptíó snpoosaY-szekvenciája é Skf| IÍ9 bíOk·3 szerinti skefevëïl és a biokompatibilis 'poíimer otetoxspölietjléórgllkíii,
  4. 7. A ül igénypotít sssírntizkoípágátöAi, sáp! aikiokomp&amp;irbiHs polimer azASöé. antinosappogleklnái. kap-csalódik a pölipepíklhez> S. Eljárás az 7, igénypont szerinti konjugÉmp élM||itáslts,:&amp;ípe:iy iariiméxms kóvsikezökst; a ntükődökópes kfílBas. kikior polipetSiäet kódoló «gy ciózteía-öí. különböző aböposávái kőtíólé: szckveooia dszlesnt kddötp iskekveneiákákvalé bejyéiiósliésé vek Ádhűtálí ísdkjeOiid--szokveneía ejtpremsliáiása, ezáltal cisztéhmel dósliókt innteiin elMllMsäi a muteist tisztítása. .á-^sai^Mt.t^^át^tt^^-^sWí^^t^P^^^ipö-í-ím.enreljrálxoÍóa bioktmpmdnilk polimer: tartató^ esópórtct, péídárd tiókj tdfiátöl, ízsAiáiop azrddint ..oxMnt, 8-pindiIt vagy rsalejmib&amp;h atnoly a bevitt eisziem kialakítja a konlygákiníop és a kphtpgábnp tisztítása. 9. Λ 8, igénypont .szerinti eljárás, ahol abktkbbtpÄiltS'polimer metoxipoHsdldn-glikoS ás g.omteio. a-gáí s iíiétaxípóiipi:iiöa-gi:ik;«ióí:i Mvö íásiekoid esogorîtid:. Ili A ti. sgáswpotk szedni? eljárás, ahol a ömték auklAdid'SzekviSaöia expressaioia a eiszteinnel dősítoit mváetribe bevitt sasbad cisSelo csepordpkjhoa kovalensen kapcsolódó szülMddl esoportökst tartalmazó sejt-le ey éssiökirxegbea törsárbk. ahol az eljárás iariaimasaa a kövétkeaó lépéseket. is a mamin ekpresszsi>|a után ás a métáin tísatMsa előtt.: (a.) a pyjtelp énaíkf^eté'ss Mlktólosgeít«! oly;»? kAAdtsönyek koalAi melyek között a mtdem enyhén redokálie dik és a sznUMddl. csoport íelskabadid, ás (K> s íeisaabadib? szuUbklni csapon és á íedstkátészer eltávolítása a. mamiobdi továbbá, éhol a MdÄt: » tedékálőszer eltávolítása után legalább 5 -percig .reagállatívk a bipkompstibilh pob-sperre i I L A 10, igénypom Surimi eljárás, aise: &amp; Vi] kas lá^oroiíUisioölyanA'líkasfáktorííaáslttíej aíneilyoak B-dománje deieiák, 12. A 1ö, igénypont seeded eljárás, abftl a »kómrnpatlbills polimer metváx%öHőt11éö»gliköbmlonní)d ds iMreiisrmatasya $~M küa, 13, öyégvászari kdsskmdny paxeatöráife beadásra, amely gyögyá&amp;zatllag elmpslèaté atpyáasí ds terápiásán Midkony pennyiségdAatteimaz 1-7. igénypontéi bármelyike szenpibkóo;k:igáiq:mhóL
  5. 14. Az i-Ά igápygotBok bármelyike szerinti konjdgányn alkalmaaása hemotsSIa kezelésére szolgáló gyógyszer előáijdásábari. 15, A 13, Igdnytrors! szerinti gyógyászati készítmény álkalrbázása iremsíkHa. kezelésére szolgáló gyógyszer előállításában.
HUE05849392A 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása HUE033776T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12

Publications (1)

Publication Number Publication Date
HUE033776T2 true HUE033776T2 (hu) 2018-01-29

Family

ID=36337298

Family Applications (5)

Application Number Title Priority Date Filing Date
HUE11153297A HUE059193T2 (hu) 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása
HUE05849392A HUE033776T2 (hu) 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása
HUE11153300A HUE060016T2 (hu) 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása
HUE16186901A HUE050542T2 (hu) 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása
HUS1900026C HUS1900026I1 (hu) 2004-11-12 2019-05-07 FVIII helyspecifikus módosítása

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE11153297A HUE059193T2 (hu) 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása

Family Applications After (3)

Application Number Title Priority Date Filing Date
HUE11153300A HUE060016T2 (hu) 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása
HUE16186901A HUE050542T2 (hu) 2004-11-12 2005-11-14 FVIII helyspecifikus módosítása
HUS1900026C HUS1900026I1 (hu) 2004-11-12 2019-05-07 FVIII helyspecifikus módosítása

Country Status (32)

Country Link
US (4) US7632921B2 (hu)
EP (9) EP2772500B1 (hu)
JP (5) JP2008524117A (hu)
KR (7) KR101468345B1 (hu)
CN (6) CN105753968A (hu)
AU (1) AU2005304622B2 (hu)
BR (2) BR122016022033B8 (hu)
CA (1) CA2586379C (hu)
CY (3) CY1119292T1 (hu)
DK (3) DK2371856T3 (hu)
ES (4) ES2821832T3 (hu)
FR (1) FR19C1031I2 (hu)
HK (3) HK1117875A1 (hu)
HN (1) HN2007015683A (hu)
HR (2) HRP20180481B1 (hu)
HU (5) HUE059193T2 (hu)
IL (3) IL182903A (hu)
LT (5) LT2371856T (hu)
LU (1) LUC00118I2 (hu)
MA (1) MA29663B1 (hu)
MX (2) MX2007005466A (hu)
NL (1) NL300989I2 (hu)
NO (3) NO345800B1 (hu)
NZ (1) NZ555032A (hu)
PH (2) PH12014500352A1 (hu)
PL (3) PL2363414T3 (hu)
PT (4) PT2363414T (hu)
RU (1) RU2423380C2 (hu)
SI (4) SI2363414T1 (hu)
UA (1) UA95225C2 (hu)
WO (1) WO2006053299A2 (hu)
ZA (1) ZA200703696B (hu)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
AU2005260763B2 (en) * 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
RU2008145084A (ru) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
EP2222329A1 (en) * 2007-11-09 2010-09-01 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
BRPI0913374A2 (pt) * 2008-06-04 2015-11-24 Bayer Healthcare Llc muteínas fviii para tratamento de doença de von willebrand
US8575104B2 (en) 2008-06-24 2013-11-05 Csl Behring Gmbh Factor VIII, von willebrand factor or complexes thereof with prolonged in vivo half-life
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
CA2738679A1 (en) * 2008-10-17 2010-04-22 Baxter International Inc. Modified blood factors comprising a low degree of water soluble polymer
KR20110093775A (ko) * 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
EP2368124A4 (en) * 2008-11-24 2012-09-19 Bayer Healthcare Llc METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
PT2393828T (pt) 2009-02-03 2017-01-18 Amunix Operating Inc Polipéptidos recombinantes estendidos e composições que compreendem os mesmos
WO2010102886A1 (en) * 2009-02-19 2010-09-16 Novo Nordisk A/S Modification of factor viii
CA2755395C (en) * 2009-03-20 2015-02-24 Hanmi Holdings Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN102573920B (zh) 2009-07-27 2015-01-14 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5813641B2 (ja) * 2009-08-24 2015-11-17 アムニクス オペレーティング インコーポレイテッド 凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
PL3326643T3 (pl) 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN102770449B (zh) 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
RS59827B1 (sr) * 2010-02-21 2020-02-28 Bayer Healthcare Llc Metoda za aktiviranje i konjugovanje biomolekula
MX365521B (es) 2010-04-15 2019-06-06 Oligasis Star Polimeros que contienen zwiteriones de alto peso molecular.
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
US9150637B2 (en) 2010-11-05 2015-10-06 Baxalta Inc. Variant of antihemophilic factor VIII having increased specific activity
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
CN103269723B (zh) 2010-12-22 2017-04-05 百深有限责任公司 用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法
WO2012166622A1 (en) 2011-05-27 2012-12-06 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
AR087020A1 (es) 2011-07-01 2014-02-05 Bayer Ip Gmbh Polipeptidos de fusion de relaxina y usos de los mismos
DK3513804T3 (da) 2011-07-08 2022-06-20 Bioverativ Therapeutics Inc Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
HUE043537T2 (hu) * 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
PL3564260T3 (pl) 2012-02-15 2023-03-06 Bioverativ Therapeutics Inc. Kompozycje czynnika viii oraz sposoby ich wytwarzania i stosowania
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
EP3693000B1 (en) 2012-06-08 2022-03-02 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
WO2014063108A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
WO2014144795A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor viii polypeptide formulations
US20160030524A1 (en) * 2013-03-15 2016-02-04 Bayer Healthcare Llc Recombinant factor viii formulations
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP3041513B1 (en) 2013-09-08 2020-08-05 Kodiak Sciences Inc. Factor viii zwitterionic polymer conjugates
EP3060242A1 (en) * 2013-10-22 2016-08-31 DBV Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
EP4332839A2 (en) 2013-12-06 2024-03-06 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
AU2015207472B2 (en) * 2014-01-20 2018-11-22 Octapharma Ag A process for manufacturing factor VIII having an improved ratio of FVIII:C/FVIII:Ag
JP6609561B2 (ja) 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
EA038573B1 (ru) 2014-03-24 2021-09-16 Биовератив Терапьютикс Инк. Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
WO2015157335A1 (en) 2014-04-10 2015-10-15 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2016000039A1 (en) 2014-07-02 2016-01-07 Csl Limited Modified von willebrand factor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
ES2774011T3 (es) 2015-05-22 2020-07-16 CSL Behring Lengnau AG Polipéptidos del factor de von Willebrand truncado para tratar la hemofilia
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
RU2018128582A (ru) 2016-01-07 2020-02-11 Цсл Беринг Ленгнау Аг Мутированный укороченный фактор фон виллебранда
CA3008448A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
KR20190073576A (ko) 2016-11-11 2019-06-26 체에스엘 베링 렝나우 아게 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
CA3043250A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CA3043702A1 (en) 2016-11-16 2018-05-24 Bayer Healthcare Llc Red blood cell targeted factor viii and method of using the same
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
US20190375822A1 (en) 2018-05-18 2019-12-12 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
WO2021113800A1 (en) * 2019-12-06 2021-06-10 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
DE69333974T2 (de) 1992-10-02 2006-08-03 Genetics Institute, LLC, Cambridge Zusammensetzung, welche den Koagulationsfaktor VIII beinhaltet; Verfahren zu deren Herstellung und die Benutzung eines Oberflächenaktiven Stoffes als Stabilisator
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
JPH09504174A (ja) 1993-10-29 1997-04-28 インサイト ファーマシューティカルズ，インク． プロテアーゼネキシン１変異体を含むキメラ蛋白
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
EP0776530A4 (en) * 1995-06-21 1998-06-10 Motorola Inc METHOD AND ANTENNA PRODUCING AN OMNIDIRECTIONAL RADIATION DIAGRAM
AU6486196A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
EP0964702B1 (en) * 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
EP1881005B1 (en) 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2001520198A (ja) * 1997-10-17 2001-10-30 ハーベスト・テクノロジーズ・コーポレイション 血小板富有血漿からの成長因子富有化フィブリノーゲン濃縮物の調製
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
ATE526401T1 (de) 1999-01-14 2011-10-15 Bolder Biotechnology Inc Verfahren zur herstellung von proteinen mit freien cysteinresten
WO2000071714A2 (en) 1999-05-24 2000-11-30 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
ES2325877T3 (es) * 2000-02-11 2009-09-23 Bayer Healthcare Llc Moleculas de tipo factor vii o viia.
MXPA03002256A (es) 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
US7615622B2 (en) 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
ES2432967T3 (es) * 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Derivados del Factor VII de coagulación
AU2002312660A1 (en) 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
DE60230456D1 (de) 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
CA2482926A1 (en) 2002-04-18 2003-10-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified factor viii
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
ATE399185T1 (de) 2002-12-31 2008-07-15 Nektar Therapeutics Al Corp Maleinsäureamid polymerderivate und ihre biokonjugate
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
CA2509939C (en) 2003-01-06 2013-05-21 Nektar Therapeutics Al, Corporation Thiol-selective water-soluble polymer derivatives
HUE058897T2 (hu) 2003-02-26 2022-09-28 Nektar Therapeutics Polimer VIII-as faktor egység konjugátumok
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050107297A1 (en) * 2003-05-12 2005-05-19 Holmes Christopher P. Novel poly(ethylene glycol) modified compounds and uses thereof
LT2644206T (lt) 2003-05-23 2019-05-27 Nektar Therapeutics Peg dariniai, susidedantys iš dviejų peg grandinių
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US20050123997A1 (en) 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
ATE463572T1 (de) 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates

Also Published As

Publication number Publication date
NO344606B1 (no) 2020-02-10
RU2007121517A (ru) 2008-12-20
NL300989I2 (nl) 2019-11-28
JP2017105773A (ja) 2017-06-15
JP6487895B2 (ja) 2019-03-20
EP1824988B1 (en) 2017-04-19
WO2006053299A3 (en) 2006-08-24
JP6559642B2 (ja) 2019-08-14
EP3323829B1 (en) 2020-07-15
PL2363414T3 (pl) 2022-09-05
FR19C1031I1 (hu) 2019-06-28
UA95225C2 (ru) 2011-07-25
HK1117875A1 (en) 2009-01-23
US20160051633A1 (en) 2016-02-25
EP3153181A1 (en) 2017-04-12
CN103214569A (zh) 2013-07-24
EP2772500A1 (en) 2014-09-03
ES2930143T3 (es) 2022-12-07
BR122016022033B1 (pt) 2021-03-02
HUE059193T2 (hu) 2022-10-28
PT2363414T (pt) 2022-08-04
CN105753968A (zh) 2016-07-13
AU2005304622B2 (en) 2012-03-29
KR20120136413A (ko) 2012-12-18
US20060115876A1 (en) 2006-06-01
EP3243833A1 (en) 2017-11-15
CN103102406B (zh) 2015-05-27
CY2019024I2 (el) 2019-11-27
CN107082806A (zh) 2017-08-22
PT3130601T (pt) 2020-10-01
WO2006053299A2 (en) 2006-05-18
EP3243833B1 (en) 2020-06-17
HUE050542T2 (hu) 2020-12-28
NO20072997L (no) 2007-06-27
ES2930159T3 (es) 2022-12-07
CY1123384T1 (el) 2021-12-31
EP2772500B1 (en) 2019-12-25
CN105148287B (zh) 2019-07-09
US9096656B2 (en) 2015-08-04
NZ555032A (en) 2010-02-26
CA2586379C (en) 2012-04-03
EP2363414A3 (en) 2012-03-21
BR122016022033B8 (pt) 2021-05-25
KR20140091618A (ko) 2014-07-21
KR101904630B1 (ko) 2018-10-04
IL182903A (en) 2014-09-30
DK2371856T3 (en) 2022-08-08
KR20160105928A (ko) 2016-09-07
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
JP2017101028A (ja) 2017-06-08
EP3243834A1 (en) 2017-11-15
CN103214569B (zh) 2016-12-28
IL232540A0 (en) 2014-06-30
MX2007005466A (es) 2007-10-19
BRPI0517795A (pt) 2008-10-21
EP2363414A2 (en) 2011-09-07
PL1824988T3 (pl) 2018-01-31
PH12014500352B1 (en) 2015-07-20
US20130274445A1 (en) 2013-10-17
CY1119292T1 (el) 2018-02-14
PH12019501613A1 (en) 2020-09-14
ES2821832T3 (es) 2021-04-27
KR20130036780A (ko) 2013-04-12
IL234433B (en) 2019-11-28
HN2007015683A (es) 2011-07-11
JP6109523B2 (ja) 2017-04-05
EP2371856A3 (en) 2012-03-14
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
KR20140019489A (ko) 2014-02-14
BRPI0517795B8 (pt) 2021-05-25
LUC00118I2 (hu) 2019-12-27
LT2363414T (lt) 2022-10-25
LTPA2019509I1 (lt) 2019-08-26
MX350293B (es) 2017-09-04
ZA200703696B (en) 2008-08-27
LT3130601T (lt) 2020-09-10
US9364520B2 (en) 2016-06-14
CN101124331A (zh) 2008-02-13
CN103102406A (zh) 2013-05-15
HRP20180481A2 (hr) 2018-06-29
DK1824988T3 (en) 2017-08-07
LTC1824988I2 (lt) 2021-02-25
BRPI0517795B1 (pt) 2020-03-31
CN105148287A (zh) 2015-12-16
RU2423380C2 (ru) 2011-07-10
JP2008524117A (ja) 2008-07-10
LT1824988T (lt) 2017-10-25
KR101654011B1 (ko) 2016-09-05
ES2633916T3 (es) 2017-09-26
EP1824988A4 (en) 2008-12-31
SI1824988T1 (sl) 2017-11-30
NL300989I1 (nl) 2019-05-22
US7632921B2 (en) 2009-12-15
EP2363414B1 (en) 2022-05-18
MA29663B1 (fr) 2008-08-01
HRP20070268B1 (hr) 2018-04-20
CN101124331B (zh) 2013-04-24
EP3130601B1 (en) 2020-07-15
IL232540A (en) 2017-08-31
EP2371856B1 (en) 2022-05-18
PT2371856T (pt) 2022-08-12
NO20200044A1 (no) 2007-06-27
PH12014500352A1 (en) 2015-07-20
HUS1900026I1 (hu) 2022-04-28
KR20180110192A (ko) 2018-10-08
DK2363414T3 (da) 2022-08-08
EP2371856A2 (en) 2011-10-05
NO345800B1 (no) 2021-08-09
PL2371856T3 (pl) 2022-08-22
AU2005304622A1 (en) 2006-05-18
JP2015134780A (ja) 2015-07-27
SI2371856T1 (sl) 2022-09-30
US20100081615A1 (en) 2010-04-01
CY2019024I1 (el) 2019-11-27
EP1824988A2 (en) 2007-08-29
HRP20070268A2 (en) 2007-09-30
FR19C1031I2 (fr) 2020-06-05
JP2013067621A (ja) 2013-04-18
KR101243564B1 (ko) 2013-03-27
HRP20180481B1 (hr) 2022-02-18
LT2371856T (lt) 2022-08-25
SI3130601T1 (sl) 2020-11-30
LUC00118I1 (hu) 2019-05-13
PT1824988T (pt) 2017-07-21
CA2586379A1 (en) 2006-05-18
IL182903A0 (en) 2007-08-19
KR101483917B1 (ko) 2015-01-16
EP3130601A1 (en) 2017-02-15
HUE060016T2 (hu) 2023-01-28
BRPI0517795A8 (pt) 2018-12-26
HK1182121A1 (en) 2013-11-22
HK1218718A1 (zh) 2017-03-10
EP3323829A1 (en) 2018-05-23
KR101468345B1 (ko) 2014-12-03

Similar Documents

Publication Publication Date Title
EP1824988B1 (en) Site-directed modification of fviii
WO2009149303A1 (en) Fviii muteins for treatment of von willebrand disease
AU2016203693B2 (en) Site-directed modification of FVIII
AU2012203813B2 (en) Site-directed modification of FVIII
AU2013203348B2 (en) Site-directed modification of FVIII